Jain Global’s Inhibikase Therapeutics IKT Stock Holding History

Jain Global’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-54,845	Closed	-$120K	–	1390
2025 Q1	$120K	Buy	+54,845	New	+$138K	﹤0.01%	949

Other funds holding IKT

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jain Global's IKT Position: Q2 2025 in Review

Jain Global sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 54,845 shares — an estimated $120K sold.

Jain Global first reported a position in IKT in Q1 2025 and held it in 1 quarter. The position peaked at $120K in Q1 2025. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

Jain Global reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
Jain Global sold 54,845 Inhibikase Therapeutics shares in Q2 2025, an estimated $120K.
Jain Global first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 1 quarter.
Jain Global's Inhibikase Therapeutics position peaked at $120K in Q1 2025.
48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on Jain Global's 13F filing for Q2 2025, filed 14 Aug 2025.